CN107530298B - 利用酪氨酸激酶抑制剂的组合物和方法 - Google Patents

利用酪氨酸激酶抑制剂的组合物和方法 Download PDF

Info

Publication number
CN107530298B
CN107530298B CN201680018121.6A CN201680018121A CN107530298B CN 107530298 B CN107530298 B CN 107530298B CN 201680018121 A CN201680018121 A CN 201680018121A CN 107530298 B CN107530298 B CN 107530298B
Authority
CN
China
Prior art keywords
mice
pzr
dasatinib
tyrosine
phosphorylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680018121.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN107530298A (zh
Inventor
A·班尼特
J-S·易
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Priority to CN202110533185.2A priority Critical patent/CN113244399A/zh
Publication of CN107530298A publication Critical patent/CN107530298A/zh
Application granted granted Critical
Publication of CN107530298B publication Critical patent/CN107530298B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201680018121.6A 2015-01-26 2016-01-26 利用酪氨酸激酶抑制剂的组合物和方法 Active CN107530298B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110533185.2A CN113244399A (zh) 2015-01-26 2016-01-26 利用酪氨酸激酶抑制剂的组合物和方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562107553P 2015-01-26 2015-01-26
US62/107,553 2015-01-26
US201562250052P 2015-11-03 2015-11-03
US62/250,052 2015-11-03
PCT/US2016/014882 WO2016123086A1 (en) 2015-01-26 2016-01-26 Compositions and methods of using tyrosine kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110533185.2A Division CN113244399A (zh) 2015-01-26 2016-01-26 利用酪氨酸激酶抑制剂的组合物和方法

Publications (2)

Publication Number Publication Date
CN107530298A CN107530298A (zh) 2018-01-02
CN107530298B true CN107530298B (zh) 2021-06-04

Family

ID=56544226

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680018121.6A Active CN107530298B (zh) 2015-01-26 2016-01-26 利用酪氨酸激酶抑制剂的组合物和方法
CN202110533185.2A Pending CN113244399A (zh) 2015-01-26 2016-01-26 利用酪氨酸激酶抑制剂的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110533185.2A Pending CN113244399A (zh) 2015-01-26 2016-01-26 利用酪氨酸激酶抑制剂的组合物和方法

Country Status (7)

Country Link
US (4) US10471059B2 (enExample)
EP (2) EP3250192B1 (enExample)
JP (4) JP6854766B2 (enExample)
CN (2) CN107530298B (enExample)
HK (1) HK1245678A1 (enExample)
MX (2) MX2017009643A (enExample)
WO (1) WO2016123086A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
CN106943595A (zh) * 2017-03-30 2017-07-14 福州大学 Src/Abl抑制剂作为预防或治疗辐射损伤药物的应用
KR20200138283A (ko) 2018-03-22 2020-12-09 바이킹 테라퓨틱스 인코포레이티드 결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법
EP3823615A4 (en) * 2018-06-18 2022-04-06 Duke University Compositions and methods for treating disorders characterized with aberrant ras/mapk signaling
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
US20220117966A1 (en) * 2019-02-27 2022-04-21 Astrazeneca Ab Method of treating fibrosis
WO2021119525A1 (en) * 2019-12-11 2021-06-17 Tiaki Therapeutics Inc. Shp1 and shp2 inhibitors and their methods of use
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
WO2022125551A1 (en) * 2020-12-07 2022-06-16 Hht Foundation International, Inc. Method of treating hereditary hemorrhagic telangiectasia using pazopanib
WO2023127012A1 (ja) * 2021-12-27 2023-07-06 国立研究開発法人理化学研究所 動脈瘤の治療及び／又は予防のための医薬組成物、動脈瘤の診断補助方法、並びに動脈瘤治療薬の評価方法
US20250195519A1 (en) * 2022-03-18 2025-06-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of dasatinib and lovastatin for use in methods for the treatment of cardiac fibrosis
CN116832040A (zh) * 2023-06-12 2023-10-03 北京市心肺血管疾病研究所 细胞周期蛋白依赖性激酶抑制剂在治疗射血分数保留型心力衰竭中的应用
WO2025031474A1 (en) * 2023-08-10 2025-02-13 Insilico Medicine Ip Limited Method and medicament for treating endometriosis
WO2025111752A1 (zh) * 2023-11-27 2025-06-05 中山大学 以Lck/Fyn介导STAT3磷酸化为靶点的阻断剂和生物材料的用途
WO2025170008A1 (ja) * 2024-02-07 2025-08-14 国立大学法人京都大学 成熟心筋細胞の製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355786B1 (en) * 1998-10-30 2002-03-12 Vanderbilt University Purified and isolated protein zero related (PZR) and therapeutic and screening methods using same
CA2388343A1 (en) * 1999-11-12 2001-05-17 Mark Steven Marshall Methods for inhibiting neurofibromatosis type 1 (nf1)
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
WO2006029319A2 (en) 2004-09-09 2006-03-16 The General Hospital Corporation Modulating phosphatase activity in cardiac cells
US20070015777A1 (en) * 2005-07-14 2007-01-18 Myogen, Inc. Use of Inhibitors of the Ubiquitin Proteasome Pathway as a Method of Increasing Contractility of the Heart
US20070123539A1 (en) * 2005-10-20 2007-05-31 University Of South Florida Treatment of Restenosis and Stenosis with Dasatinib
GB0609962D0 (en) 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
EP2086528B1 (en) 2006-10-31 2016-10-26 University Of Toledo Na+/k+-atpase-specific peptide inhibitors of src and src family kinases
US20090123390A1 (en) 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
EP2359813A1 (en) * 2010-02-04 2011-08-24 Ratiopharm GmbH Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid
EP2988738A4 (en) * 2013-01-10 2016-11-09 Pulmokine Inc THERAPEUTIC INDICATIONS OF KINASE INHIBITORS
AU2014287209B2 (en) * 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease

Also Published As

Publication number Publication date
EP3250192A4 (en) 2018-09-26
MX2017009643A (es) 2018-05-04
US20230036788A1 (en) 2023-02-02
JP2021050218A (ja) 2021-04-01
HK1245678A1 (zh) 2018-08-31
MX2022012505A (es) 2022-11-07
US20250360129A1 (en) 2025-11-27
US20200009142A1 (en) 2020-01-09
CN107530298A (zh) 2018-01-02
US10471059B2 (en) 2019-11-12
EP4653015A2 (en) 2025-11-26
CN113244399A (zh) 2021-08-13
EP3250192A1 (en) 2017-12-06
US20180271864A1 (en) 2018-09-27
JP6854766B2 (ja) 2021-04-07
JP2018504416A (ja) 2018-02-15
EP3250192B1 (en) 2025-10-08
CA2974958A1 (en) 2016-08-04
US11458137B2 (en) 2022-10-04
JP2025061369A (ja) 2025-04-10
WO2016123086A1 (en) 2016-08-04
JP2023052878A (ja) 2023-04-12

Similar Documents

Publication Publication Date Title
CN107530298B (zh) 利用酪氨酸激酶抑制剂的组合物和方法
Zhao et al. An essential role for Wnt/β-catenin signaling in mediating hypertensive heart disease
Song et al. CREG protects from myocardial ischemia/reperfusion injury by regulating myocardial autophagy and apoptosis
JP7461071B2 (ja) クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ
Wu et al. Pharmacological inhibition of c-Jun N-terminal kinase signaling prevents cardiomyopathy caused by mutation in LMNA gene
JP7570100B2 (ja) 老化細胞を除去する方法、および老化細胞の調製方法
Ranek et al. Muscarinic 2 receptors modulate cardiac proteasome function in a protein kinase G-dependent manner
Choi et al. Elevated dual specificity protein phosphatase 4 in cardiomyopathy caused by lamin A/C gene mutation is primarily ERK1/2-dependent and its depletion improves cardiac function and survival
Schramm et al. New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling
Xu et al. Ghrelin ameliorates hypoxia-induced pulmonary hypertension via phospho-GSK3 b/b-catenin signaling in neonatal rats
KR20180035739A (ko) 조직 재생 및 저하된 조직 기능의 회복을 자극하기 위한 제제로서의 디카르복시산의 비스아미드 유도체
JP2025041721A (ja) Ｐｐ２ａアンカリングの阻害による心疾患の処置
HK40057503A (en) Compositions and methods of using tyrosine kinase inhibitors
CA2974958C (en) Compositions and methods of using tyrosine kinase inhibitors
O'Neill IV et al. Germline deletion of FAK-related non-kinase delays post-natal cardiomyocyte mitotic arrest
CA3247585A1 (en) TREATMENT OF MUSCLE FIBROSIS
Song et al. FOXM1 Protects Against Myocardial Ischemia‐Reperfusion Injury in Rodent and Porcine Models by Suppressing MKRN1‐Dependent LKB1 Ubiquitination
JP7525591B2 (ja) 心機能不全を予測及び処置するための方法
Wang et al. Kielin/chordin-like protein (KCP) deficiency exacerbates doxorubicin-induced myocardial injury by promoting macrophage M1 polarization through autophagy inhibition.
US20250134889A1 (en) Targeting ire1 kinase and fmrp for prophylaxis, management and treatment of atherosclerosis
Haufe The role of transient fetal hypoxia in the development of pulmonary hypertension dependent on p22phox
KR20220094328A (ko) DEAD-box 단백질 억제제를 포함하는 B형 간염 바이러스에 대한 항 바이러스용 조성물
Editors Circulation Editors’ Picks: Most Read Articles on Studies Performed in an Animal Model
JPWO2004073740A1 (ja) 組織内アンジオテンシンｉｉ産生亢進制御剤並びに動脈硬化症、心・脳血管疾患及び／若しくは糖尿病合併症の発症予防又は治療剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant